FDA Novel Switch Meeting Shows Gulf Between Interests
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug manufacturers and physicians are at odds with the pharmacy industry’s expectations for the role pharmacists will have in distributing novel switches. At an FDA public hearing, CDER Director Janet Woodcock says the agency expects to “extend the concept of self-diagnosis and self-treatment to additional drugs.”
You may also be interested in...
Perrigo Reports Broad Growth, But Investors Sour On Turnaround's Price Tag
OTC Incontinence Device Ad Claims Sunk In UK, But US Label Claims Have FDA OK
Electrolyte Supplements’ Benefit For Sodium Level A ‘False Paradigm’ – Study
Stanford University and other researchers concluded that supplements popular with endurance runners can't be relied on to keep essential sodium levels in balance. "Electrolyte supplements are promoted as preventing nausea and cramping caused by low salt levels, but this is a false paradigm. They've never been shown to prevent illness or even improve performance," says lead researcher Grant Lipman.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: